Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.61 |
| ▸ | CNR1 | P21554 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12095640 | 0.83 | CNR1 (0.58) | CNR2CNR1 | |
| SCHEMBL1464485 | 0.82 | CNR2 (0.65) | CNR2CNR1KMT2AKDM4ELMNA | |
| SCHEMBL1464948 | 0.82 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL1465765 | 0.81 | KDM4E (0.52) | CNR2CNR1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL1464865 | 0.81 | CNR2 (0.63) | CNR2CNR1SMN1; SMN2LMNARAB9A | |
| SCHEMBL1464396 | 0.81 | CNR2 (0.63) | CNR2CNR1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL1463634 | 0.81 | CNR2 (0.66) | CNR2CNR1 | |
| SCHEMBL12635497 | 0.80 | CNR2 (0.57) | CNR2CNR1RAB9ANPC1HTT | |
| SCHEMBL1464328 | 0.80 | CNR2 (0.65) | CNR2CNR1 | |
| SCHEMBL1464740 | 0.80 | CNR2 (0.58) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | claimed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | claimed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | claimed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-7935715-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885KMT2A 3627/4885 |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885KMT2A 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.